Critical Insights From TransMedics Gr Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the past three months, 9 analysts have provided ratings for TransMedics Group (NASDAQ:TMDX), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 19.19% to $128.89. Analysts have recently raised their price targets, reflecting positive expectations for the company's performance.
June 21, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics Group (NASDAQ:TMDX) has received positive analyst ratings over the past three months, with a notable increase in the average 12-month price target to $128.89. Analysts have raised their price targets, indicating strong expectations for the company's future performance.
The increase in the average 12-month price target and the positive sentiment from multiple analysts suggest a strong short-term outlook for TMDX. The raised price targets reflect confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100